Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott

This article was originally published in The Gray Sheet

Executive Summary

Response to FDA consent decree final inspection observations is being prepared for submission "in a timely manner" following Jan. 18 close-out meeting with FDA, VP John Thomas reports Jan. 29 at the U.S. Bancorp Piper Jaffray Health Care Conference in New York City ("The Gray Sheet" Jan. 21, 2002, p. 9). Digene notes it has re-acquired from Abbott exclusive rights to distribute Digene's chlamydia and gonorrhea (CT/GC) tests and accessories worldwide, allowing Digene to market tests for human papillomavirus, chlamydia and gonorrhea from a single specimen...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT016028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel